For personal use only

ASX Release
22 October 2024

ASX code: PIQ

Quarterly Activities Report

Proteomics International Laboratories Ltd (Proteomics International; the Company; ASX: PIQ), a pioneer in predictive diagnostics and precision medicine is pleased to provide the following update on its business activities for the three months to 30 September 2024 and subsequent to the period end.

- **World first blood test for esophageal cancer shows 94% accuracy:** results demonstrated outstanding diagnostic performance for identifying patients with esophageal adenocarcinoma (EAC) in a clinical validation study.
- **Groundbreaking study on PromarkerD and type 1 diabetes and kidney health:** results show PromarkerD demonstrated high accuracy in predicting chronic kidney disease in this new group of patients (all previous applications were directed at patients with type 2 diabetes).
- **Update on commercialisation of PromarkerD:** Proteomics International is targeting a US launch in H1 CY25, and an Australian launch in Q1 CY25 through a hybrid approach of traditional licensing and direct-to-consumer/patient (DTC/DTP) Go-to-Market strategies.
- **PromarkerEndo and PromarkerEso tests advance**
- **Analytical Services:** ISO 17025 certification successfully renewed following audit by National Association of Testing Authorities (NATA).
- **Events and Marketing**
- **Financial and Corporate Highlights:** Appointment of Dr James Williams as an independent non-executive director and deputy chair.
- **Target share price catalysts FY25**



Proteomics International Laboratories Ltd
ABN 78 169 979 971
Box 3008, Broadway, Nedlands, WA 6009, Australia
T: +61 8 9389 1992 | E: enquiries@proteomicsinternational.com | W: www.proteomicsinternational.com

For personal use only

OPERATIONAL HIGHLIGHTS – ENABLING PRECISION MEDICINE

Proteomics International's activities fall into three strategic areas:

I. Commercialisation of the Company's pipeline of precision diagnostics
II. Precision diagnostic tests in development
III. Specialist accredited analytical services on a commercial basis

Proteomics International is at the forefront of predictive diagnostics and precision medicine. The Company now has a suite of diagnostic tests at the commercialisation and pre-commercialisation stage, with the PromarkerD, PromarkerEndo, PromarkerEso and OxiDx tests each at pivotal points in their advancement.

Go-to-Market pathways for the Company's suite of novel diagnostic tests

Advances in digital health and direct-to-consumer healthcare, driven by essential changes in medical practice due to the global pandemic and evolution of social and digital media, are transforming previously expensive and low volume routes to market for diagnostic testing into cost-effective and exciting opportunities. Digital media platforms and established e-commerce practices mean the consumer can now choose to by-pass traditional pathways.

Proteomics International is engaged with multiple potential partners across all aspects of the supply/provider chain to accelerate the commercial roll-out of its tests. To achieve early revenue the Company is targeting specialist adoption routes through laboratories that utilise the ISO 15189 international standard or the US Laboratory Developed Test (LDT) pathway for CLIA certified clinical laboratories. These pathways closely align with the Promarker test platform and Proteomics International's expertise, and can simultaneously form the bases for implementing hybrid Go-to-Market models, e.g. traditional & digital.

Potential Go-to-Market strategies are shown below.



For personal use only

PROMARKERD COMMERCIALISATION ACTIVITIES

PromarkerD is a cutting-edge diagnostic test specifically designed to predict the risk of diabetic kidney disease (DKD) in individuals with diabetes up to four years in advance of clinical symptoms. It provides a significant advancement in diabetes management by enabling early detection and intervention, which are crucial for preventing or delaying the progression of this serious complication to end stage renal disease (dialysis or kidney transplant).

Proteomics International unveils groundbreaking study on type 1 diabetes and kidney health

[ASX: 23 August] Proteomics International presented exciting new results for the PromarkerD predictive test at the Australasian Diabetes Conference in Perth, Australia, in a study titled *"Application of a validated prognostic protein biomarker test for renal decline in type 2 diabetes to type 1 diabetes: The Fremantle Diabetes Study Phase II".* The results have also been published in the journal of *Clinical Diabetes and Endocrinology* [ASX: 11 October]. This pioneering research marks the Company's first venture into the realm of type 1 diabetes and opens a new route for commercialisation of PromarkerD.

The results demonstrated the PromarkerD test had strong predictive accuracy, and the area under the receiver operating characteristic curve (AUC) was an impressive 0.93, indicating excellent performance in predicting CKD risk and kidney function decline in type 1 diabetes patients.

Diabetes affects over 537 million people worldwide, and chronic kidney disease is a major complication, leading to severe health outcomes and increased mortality. Type 1 diabetes represents approximately 10% of all cases of diabetes and cannot be prevented[1]. Diabetes has emerged as the largest single cause of end stage renal disease (leading to dialysis or kidney transplant) in developed and developing countries[2]. These preliminary findings suggest that the PromarkerD test is a highly effective prognostic tool for renal decline in both type 1 and type 2 diabetes, heralding a new era in diabetic kidney disease management.

Update on commercialisation of PromarkerD

[ASX: 19 September] Proteomics International is targeting a US launch of PromarkerD in 1H CY25 using a hybrid of two Go-to-Market strategies, namely licensing to alternative pathology laboratories and service providers, and direct to consumer/patient (DTC/DTP) (see above). The Company is also in discussions with appropriate service providers/partners to enable commercial sales. This follows the termination of Proteomics International's exclusive licence agreement with Sonic Healthcare USA for the use and commercialisation of the PromarkerD predictive test in the United States of America, after certain milestones and key performance indicators were not met [ASX: 11 September].

Proteomics International is also targeting an Australian launch of PromarkerD in Q1 CY25 through the DTC/DTP route and establishment of an ISO 15189 (clinical certification) laboratory. This capability closely aligns with the Company's existing ISO 17025 (analytical testing) and ISO 13485 (manufacturing) accreditations (see also Analytical Services below).

Further information about PromarkerD is available through the web portal (www.PromarkerD.com)

To visit the PromarkerD virtual product display please see: www.PromarkerD.com/product

PRECISION DIAGNOSTIC TESTS – THE PROMARKER™ PIPELINE

Proteomics International develops novel precision health and predictive diagnostic tests using its proprietary biomarker discovery platform called Promarker™. This disruptive technology searches for protein 'fingerprints' in a sample and can identify protein biomarkers that distinguish between people who have a disease and people who do not, using only a simple blood test. It is a powerful alternative to genetic testing. The technology is so versatile it can be used to identify fingerprints from any biological source, from wheat

[1] International Diabetes Federation 2021
[2] pubmed.ncbi.nlm.nih.gov/31767176/

seeds to human plasma. The Promarker™ platform technology has broad applicability and is being used to produce multiple new diagnostic tests to address significant unmet medical and commercial needs.

During the quarter, Proteomics International continued to progress its endometriosis, esophageal cancer and oxidative stress diagnostics towards the commercialisation phase.

PromarkerEndo

Endometriosis is a common and painful disease that affects approximately one in nine women and girls, often starting in teenagers (see PIQ Annual Report 2024). It occurs when tissue similar to the lining of the uterus grows in other parts of the body where it does not belong. At the moment, there is no simple way to test for the condition, which can cause pain and infertility, and costs Australia alone $9.7 billion each year.

The current gold standard for detection is an invasive laparoscopy followed by histopathology, a surgical procedure where a camera is inserted into the pelvis through a small cut in the abdominal wall and then a biopsy is taken for analysis. On average, it takes women 7.5 years to be diagnosed[3].

The Company is pursuing multiple avenues to ensure its novel blood test for endometriosis is commercial ready via a single or hybrid Go-to-Market strategy, with a target launch date of Q2 CY25. Test status:

- Prototype test identified up to 90% of patients with the disease (presented at World Endometriosis Conference, May 2023)
- Patents pending in all major jurisdictions
- Prototype test showed limitations in diagnosing symptomatic patients from minimal & mild endometriosis
- Advanced statistical modelling performed to distinguish symptomatic patients from minimal & mild endometriosis
- New clinical results submitted for peer review publication
- Diagnostic algorithm is being refined using 'traffic light' system to improve test performance for clinical use
- Analysis of samples from the University of Oxford [ASX: 25 March] is ongoing
- Development of the PromarkerEndo Hub for reporting patient results has commenced
- Analytical methodology is being adapted for use in a clinical environment
- Proteomics International preparing to launch PromarkerEndo in Australia under ISO 15189 accreditation, targeting Q2 CY25
- Partnering discussions are advancing

PromarkerEso

Esophageal adenocarcinoma (EAC) is the most common form of esophageal cancer and an area of significant unmet medical need, with 1 in 20 cancer deaths worldwide in 2018 attributed to esophageal cancer[4]. The five-year survival rate for EAC is less than 20% because it is frequently diagnosed too late for effective treatment.

Men over 50 with a history of obesity face elevated risk of EAC, alongside risk factors such as chronic acid reflux, also known as gastroesophageal reflux disease (GERD). Barrett's Esophagus is the only known precursor to EAC, however, 95% of people with Barrett's Esophagus never develop EAC and 95% of patients diagnosed with EAC have no preceding diagnosis of Barrett's Esophagus[5].

Current gold-standard screening for the disease requires a specialist endoscopy, an invasive procedure that costs between £1,000-2,000 in the UK[6], and US$2,750 in the United States[7], where total expenditure on treating EAC was US$2.9 billion in 2018. In the US 1.5 million endoscopies with biopsy are performed annually

[3] www.endometriosis-uk.org/endometriosis-facts-and-figures
[4] Nature Reviews Gastroenterology & Hepatology, 2021, doi.org/10.1038/s41575-021-00419-3
[5] www.cancer.org.au/assets/pdf/9-august-2020
[6] digestivehealthyuk.com/test/endoscopy-gastroscopy/answerpack/endoscopy-faq/how-much-does-an-endoscopy-cost/
[7] www.newchoicehealth.com/endoscopy/cost, JAMA Network Open, 2021, doi:10.1001/jamanetworkopen.2021.27784

For personal use only

in individuals with chronic acid reflux symptoms, but despite this up to 90% of EAC cases continue to go undetected[8].

The Company is pursuing multiple avenues to ensure its novel blood test for esophageal cancer is commercial ready via a single or hybrid Go-to-Market strategy, with a target launch date of Q1 CY25. Test status:

- PromarkerEso showed 94% accuracy in diagnosing patients with and without the disease in a clinical validation study (presented at World Congress Esophageal Diseases, September 2024)
- Patents granted in Europe, China, Australia; USA pending
- Diagnostic algorithm refined using 'traffic light' system to improve test performance for clinical use
- Development of the PromarkerEso Hub for reporting patient results has commenced
- Analytical methodology has been adapted for use in a clinical environment
- Proteomics International preparing to launch PromarkerEso in Australia under ISO 15189 accreditation, targeting Q1 CY25
- Partnering discussions are underway

World first blood test for esophageal cancer shows 94% accuracy in clinical validation study

[ASX: 23 September] Proteomics International announced outstanding results for its world-first diagnostic blood test to identify esophageal adenocarcinoma, PromarkerEso. The results from the Company's clinical validation study were presented at the 20th annual ISDE World Congress for Esophageal Diseases, in Edinburgh, Scotland (22-24 September).

Esophageal adenocarcinoma (EAC) is the predominant type of esophageal cancer in North America, Australia and Europe[9], and 1-2% of western population are considered at-risk for developing this cancer[10]. The prevalence of EAC has increased dramatically worldwide, with a six-fold increase over the last 40 years[11], and it has become the 6th leading cause of cancer-related death and 7th most common cancer, now affecting more than 600,000 people globally each year[12].

Proteomics International's PromarkerEso blood test utilises glycoprotein biomarkers—'fingerprints' in the blood—to screen for EAC. In this clinical validation study 165 samples (N=66 EAC; N=99 healthy controls) from the Victoria Cancer Biobank were analysed to determine which individuals had EAC and which did not. The results demonstrated accuracy of 94% and an AUC of 0.93, indicating outstanding diagnostic performance for identifying patients with EAC.

ANALYTICAL SERVICES

The demand for analytical services remains steady, covering the areas of pharmacokinetic testing, biosimilars and proteomics analysis, food testing, and biomarker discovery on a contract basis. The Company continues to look for opportunities to grow these revenues, targeting the clinical trials sector for both pharmacokinetic testing and the development of companion/complementary diagnostics (CDx) through biomarker analysis.

ISO 17025 laboratory certification renewed

Proteomics International successfully renewed its ISO 17025 certification for analytical testing following audit by the National Association of Testing Authorities (NATA). The accreditation, which covers testing of healthcare, pharmaceutical and food and beverage products, recognises Proteomics International's ability to consistently achieve technically valid, traceable and reproducible results, and is valid until February 2026 (Accreditation number 16838). Proteomics International was the first laboratory in the world to receive ISO, the International Organisation for Standardisation, accreditation for proteomics services in 2009.

[8] Gastroenterology. 2022 Jul; 163(1): 163‐173; doi: 10.1053/j.gastro.2022.03.037
[9] N Engl J Med, 2014. 371(26): p. 2499-509; doi: 10.1056/NEJMra1314530
[10] American Society for Gastrointestinal Endoscopy, www.asge.org
[11] Gastroenterology. 2015; 149(2): 302–317.e1; doi: 10.1053/j.gastro.2015.04.053
[12] CA Cancer J Clin 2021 May;71(3):209-249; doi: 10.3322/caac.21660

For personal use only

EVENTS and MARKETING

During the quarter Proteomics International presented at the Australasian Diabetes Congress, Perth, Western Australia (21-23 August) and the 20th ISDE World Congress (International Society for Diseases of the Esophagus), Edinburgh, Scotland (22-24 September). The Company was also represented at the 7th Bio Connection Australia, Melbourne, Victoria (29 July) and the 60th EASD Annual Meeting (European Association for the Study of Diabetes), Madrid, Spain (9-13 September). These events align with the Company's objective of actively engaging with potential users of its technology to foster awareness, adoption and uptake of its novel diagnostic tests.

For investor engagement, the Company was represented at the 18th Bioshares Biotech Summit, Fremantle, Western Australia (12-13 July), presented at the Pitt Street Research Life Sciences Conference, Sydney, New South Wales [ASX: 19 September], and took part in an investor webinar with ShareWise[13]. All PIQ announcements and related shareholder information are available from the Company's website[14].

Proteomics International engaged in several media opportunities[15] over the past quarter, with Managing Director Dr Richard Lipscombe interviewed on the Phase III podcast, discussing how the PromarkerD test could play a role in preventative healthcare in the future. An opinion piece from Dr Lipscombe explores how the digital health infrastructure and advanced medical devices will increase the opportunity for personalised care and precision medicine solutions was also published by Medhealth Insight, while an article looking at the PromarkerD test for predicting renal decline in type 1 diabetes was featured online at Medical Forum.

Forthcoming Events

During the next quarter, Proteomics International will be represented at the following events & conferences:

- **American Society of Nephrology (ASN)**; 23-27 October, San Diego, USA
- **AusBiotech;** 30 October-1 November, Melbourne, Australia
- **Annual Academic Surgery Conference;** 15 November, Adelaide, Australia
- **ProCan Conference, 'Advancing Multi-Omics into the Clinic';** 18-19 November, Sydney, Australia
- **Royal Australian College of General Practitioners (RACGP) 2024 Conference;** 21-23 November, Perth, Australia

The **Annual General Meeting** of Proteomics International Laboratories Ltd will be held on 8 November, at the Harry Perkins Institute of Medical Research, Perth, Australia.

FINANCIAL AND CORPORATE HIGHLIGHTS

Proteomics International's business model is to bring its pipeline of novel diagnostic tests, exemplified by PromarkerD, PromarkerEndo, PromarkerEso and OxiDx, to major markets across the world, and offset the cash burn from R&D and product development through its analytical services revenue, coupled with the R&D tax incentive rebate. This diversified model enables the group to make optimum use of its resources.

Operations

[ASX: 16 September] Following the review commenced in the March Quarter Proteomics International is continuing the process of recruiting the additional Board and Management skills and experience necessary to support acceleration of its commercialisation initiatives. The Company announced the appointment of Dr James Williams to its Board as an independent non-executive director and deputy chair, effective 16 September 2024, and following the resignation of Dr Robyn Elliott [ASX: 12 August].

[13] www.proteomics.com.au/newsroom/events/

[14] www.proteomics.com.au/investors/ investors/asx/

[15] www.proteomics.com.au/newsroom/inthemedia/news-media/

For personal use only

Dr Williams is an accomplished manager, director, scientist and investor with experience covering all aspects of life-science technology translation. Over the past 25 years, as an established entrepreneur, he has been involved from startup to commercialisation, including CEO, CTO, Director and Chair roles, of numerous biotech companies which have resulted in five Food and Drug Administration (FDA) approved drugs and medical devices. He conceived the technology behind iCeutica Inc (acquired in 2011) and co-discovered the lead therapy for ASX-listed Dimerix Limited (ASX:DXB), now in Phase 3 trials for Chronic Kidney Disease.

Revenue & Expenditure

Proteomics International achieved cash receipts from customers for the September quarter of $253,000 (June quarter: $148,000). The net operating cash outflow for the September quarter was $1.46 million (cash outflow in June quarter: $2.26 million). Expenditure centred on the following areas:

- Business development and commercialisation costs for the rollout of PromarkerD
- Acceleration of the Go-to-Market strategies for PromarkerEndo and PromarkerEso
- R&D for projects in the Promarker™ diagnostics pipeline, led by PromarkerEndo, PromarkerEso and OxiDx

ASX Listing Rule 4.7C

Payments at item 6.1 of Appendix 4C of $158,000 relate to normal remuneration of Executive and Non-Executive Directors.

Cash Position

At 30 September, the Company had cash reserves of $5.10 million (30 June: $6.64 million), with these reserves to be strengthened by a forecast R&D tax incentive rebate of circa $2 million to be received in Q2 FY25.

For personal use only

For personal use only

TARGET SHARE PRICE CATALYSTS FY25

Proteomics International is targeting multiple potential share price catalysts for FY25:

Target Share Price Catalysts FY25

PromarkerD

- Generate sales revenue for PromarkerD in the USA
- Generate sales revenue for PromarkerD in Europe
- Licensing deals for PromarkerD with diagnostic, pharmaceutical or service providers in new geographic areas
- Generate sales revenue for PromarkerD in new target markets

PromarkerEndo

- Completion of international clinical validation study for PromarkerEndo
- Establishing reference laboratories to offer the PromarkerEndo diagnostic test
- First sales of PromarkerEndo

PromarkerEso

- Completion of clinical validation study for PromarkerEso [COMPLETED]
- Establishing reference laboratories to offer the PromarkerEso diagnostic test
- First sales of PromarkerEso

OxiDx

- Completion of validation and proof of concept studies for OxiDx
- First sales of OxiDx test

Promarker pipeline

- Development of new Dx tests using Promarker™ platform
- Commercialisation of Promarker platform tests as companion diagnostics (CDx)

Authorised by the Board of Proteomics International Laboratories Ltd (ASX: PIQ).
ENDS

About Proteomics International Laboratories (PILL) (www.proteomicsinternational.com)
Proteomics International (Perth, Western Australia) is a wholly owned subsidiary and trading name of PILL (ASX: PIQ), a medical technology company at the forefront of predictive diagnostics and bio-analytical services. The Company specialises in the area of proteomics – the industrial scale study of the structure and function of proteins. Proteomics International's mission is to improve the quality of lives by the creation and application of innovative tools that enable the improved treatment of disease.

For further information please contact:

Dr Richard Lipscombe
Managing Director
Proteomics International Laboratories Ltd
T: +61 8 9389 1992
E: enquiries@proteomicsinternational.com

Lisa Barnes
Public Relations
Profile Media
T: +61 416 583 672
E: lisab@profilemedia.com.au

Dirk van Dissel
Investor Relations & Corporate Advisor
Candour Advisory
T: +61 408 326 367
E: dirk@candouradvisory.com.au

Appendix 4C

Quarterly report for entities subject to Listing Rule 4.7B

Name of entity

Proteomics International Laboratories Ltd	
ABN	**Quarter ending ("current quarter")**
78 169 979 971	**30 September 2024**

Consolidated statement of cash flows		**Current Quarter $A'000**	**Year to date $A'000**
1.	**Cash flows related to operating activities**		
1.1	Receipts from Customers	253	253
1.2	Payments for		
	(a) research & development	(1,007)	(1,007)
	(b) product manufacturing & operating costs	(144)	(144)
	(c) advertising & marketing	(45)	(45)
	(d) leased assets	0	0
	(e) staff costs	(470)	(470)
	(f) administration & corporate costs	(276)	(276)
1.3	Dividends received (see note 3)	0	0
1.4	Interest received	99	99
1.5	Interest & other costs of finance paid	0	0
1.6	Income taxes paid	0	0
1.7	Government grants & tax incentives	135	135
1.8	Other (provide details if material)	0	0
1.9	**Net cash from / (used in) operating activities**	**(1,455)**	**(1,455)**
2.	**Cash flows related to investing activities**		
2.1	Payments to acquire:		
	(a) entities	0	0
	(b) businesses (see item 10)	0	0
	(c) property, plant & equipment	(16)	(16)
	(d) investments	0	0
	(e) intellectual property	0	0
	(f) other non-current assets	0	0
2.2	Proceeds from disposal of:	0	0
	(a) entities	0	0
	(b) businessess (see item 10)	0	0
	(c) property, plant & equipment	0	0
	(d) investments	0	0
	(e) intellectual property	0	0
	(f) other non-current assets	0	0
2.3	Cash flows from loans to other entities	0	0
2.4	Dividends received (see note 3)	0	0
2.5	Other (provide details if material)	0	0
2.6	**Net cash from / (used in) investing activities**	**(16)**	**(16)**

For personal use only

For personal use only

Consolidated statement of cash flows		Current Quarter $A'000	Year to date $A'000
3.	**Cash flows from financing activities**		
3.1	Proceeds from issues of equity securities (excluding convertible debt securities)	0	0
3.2	Proceeds from issue of convertible debt securities	0	0
3.3	Proceeds from exercise of options	0	0
3.4	Transaction costs related to issues of equity securities or	(2)	(2)
	convertible debt securities	0	0
3.5	Proceeds from borrowings	0	0
3.6	Repayment of borrowings	0	0
3.7	Transaction costs related to loans & borrowings	0	0
3.8	Dividends paid	0	0
3.9	Other (provide details if material)	(70)	(70)
3.10	**Net cash from / (used in) financing activities**	**(72)**	**(72)**

4.	**Net increase / (decrease) in cash and cash equivalents for the period**		
4.1	Cash & cash equivalents at beginning of period	6,641	6,641
4.2	Net cash from / (used in) operating activities (see 1.9 above)	(1,455)	(1,455)
4.3	Net cash from / (used in) investing activities (item 2.6 above)	(16)	(16)
4.4	Net cash from / (used in financing activities (item 3.10 above)	(72)	(72)
4.5	Effect of movement in exchange rates on cash held	0	0
4.6	**Cash & cash equivalents at end of quarter**	**5,098**	**5,098**

5.	**Reconciliation of cash & cash equivalents** *at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts*	**Current Quarter $A'000**	**Previous Quarter $A'000**
5.1	Bank balance	470	212
5.2	Cash deposits	4,628	6,429
5.3	Bank overdrafts	0	0
5.4	Other (provide details)	0	0
5.5	**Cash & cash equivalents at end of quarter (should equal item 4.6 above)**	**5,098**	**6,641**

6.	**Payments to related parties of the entity & their associates**	**Current Quarter $A,000**
6.1	Aggregate amount of payments to related parties and their associates included in item 1	158
6.2	Aggregate amount of payments to related parties and their associates included in item 2	0

Note: if any amounts are shown in items 6.1 or 6.2, your quarterly activity report must include a description of, and an explanation for, such payments

Payments at 6.1 relate to normal remuneration of Executive and Non-Executive Directors

7.	Financing facilities available *Note: the term "facility" includes all forms of financing arrangements available to the entity.* *Add notes as necessary for an understanding of the sources of finance available to the entity.*	Total facility amount at quarter end $A'000	Amount drawn at quarter end $A'000
7.1	Loan facilities	0	0
7.2	Credit standby arrangements	0	0
7.3	Other(please specify)	0	0
7.4	**Total financing facilities**	**0**	**0**
7.5	**Unused financing facilities available at quarter end**		**0**

7.6 Include in the box below a description of each facility above, including the lender, interest rate, maturity date and whether it is secured or unsecured. If any additional facilities have been entered into or are proposed to be entered into after quarter end, include a note providing details of those facilities as well.

N/A

8.	Estimated cash outflows for next quarter		$A'000
8.1	Net cash from / (used in) operating activities (see 1.9 above)		(1,455)
8.2	Cash and cash equivalents at quarter end (Item 4.6)		5,098
8.3	Unused financing facilities available at quarter end (Item 7.5)		0
8.4	Total available funding (Item 8.2 + Item 8.3)		5,098
8.5	**Estimated quarters of funding available at quarter end (Item 8.4 divided by Item 8.1)**		**3.3***

**Excludes R&D tax incentive rebate of circa $2m expected to be received in the December quarter.*

8.6 If Item 8.5 is less than 2 quarters, please provide answers to the following questions:

8.6.1 Does the entity expect that it will continue to have the current level of net operating cash flows for the time being and, if not, why not?

Answer:

8.6.2 Has the entity taken any steps, or does it propose to take any steps, to raise further cash to fund its operations and, if so, what are those steps and how likely does it believe that they will be successful?

Answer:

8.6.3 Does the entity expect to be able to continue its operations and to meet it's business objectives and, if so, on what basis?

Answer:

Note: where item 8.5 is less than 2 quarters, all of the questions 8.6.1, 8.6.2 and 8.6.3 above must be answered.

For personal use only

Compliance Statement

1 This statement has been prepared in accordance with accounting standards and policies which comply with Listing Rule 19.11A.

2 This statement gives a true and fair view of the matters disclosed.

Date: 22 October 2024

Authorised by: The Board

(Name the body or officer authorising release - see note 4)

Notes

1. The quarterly cash flow report and the accompanying activity report provide a basis for informing the market about the entities activities for the past quarter, how they have been financed and the effect this has had on the cash position. An entity that wishes to disclose additional information over and above the minimum required under the Listing Rules is encouraged to do so.

2. If this quarterly cash flow report has been prepared in accordance with Australian Accounting Standards, the definitions in, and provisions of AASB 107: Statement of Cash Flows apply to this report. If this quarterly report has been prepared in accordance with other accounting standards agreed by ASX pursuant to Listing Rule 19.11A, the corresponding equivalent standard applies to this report.

3. Dividends received may be classified either as cash flows from operating activities or cash flows from investing activities, depending on the accounting policy of the entity.

4. If this report has been authorised for release to the market by your board of directors, you can insert here: "By the board". If it has been authorised for release to the market by a committee of your board of directors, you can insert here: "By the [name of board committee-eg Audit and Risk Committee]". If it has been authorised for release to the market by a disclosure committee,you can insert here: "By the Disclosure Committee".

5. If this report has been authorised for release to the market by your board of directors and you wish to hold yourself out as complying with recommendation 4.2 of the ASX Corporate Governance Council's Corporate Governance Principles and Recommendations, the board should have received a declaration from its CEO and CFO that, in their opinion, the financial records of the entity have been properly maintained, that this report complies with the appropriate accounting standards and gives a true and fair view of the cash flows of the entity, and that their opinion has been formed on the basis of a sound system of risk management and internal control which is operating effectively.

For personal use only